Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

40%

2 of 5 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 1

3(60.0%)

Phase 2

1(20.0%)

Phase 3

1(20.0%)

5Total

Phase 1(3)

Phase 2(1)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT04671082Phase 3Completed

Efficacy and Safety of Tolperisone in Subjects With Pain Due to Acute Back Muscle Spasm

Role: lead

NCT04465266Phase 1Completed

A Phase 1 PK Study of Tolperisone in Healthy Subjects

Role: lead

NCT03802565Phase 2Completed

Tolperisone in Acute Muscle Spasm of the Back

Role: lead

NCT03353922Phase 1Completed

Driving Simulation to Assess Non-Sedative Effects of Tolperisone

Role: lead

NCT04407377Phase 1Completed

Effects of Tolperisone on Measures of Drowsiness and Cognitive Function

Role: lead

All 5 trials loaded